Citicoline is a brain chemical that occurs naturally in the body. As a medicine, it is taken by mouth as a supplement or given as an injection into the vein (by IV) or as a shot into the muscle.
In Japan and Europe, Citicoline was originally used as a prescription drug to help improve memory, thinking, and brain function in people who are healing from a stroke. It is primarily used as a dietary supplement in the U.S.
Citicoline is taken by mouth or given as an injection to help memory loss due to aging, improve vision in people with glaucoma, and help with recovery in stroke patients. It is also used for Alzheimer disease, Parkinson disease, bipolar disorder, lazy eye, and other conditions of the brain. But there is no good scientific research to support these other uses.
Is a Form of:
Also Known As:
5'-Cytidine diphosphate choline, CDPC, CDP Choline, CDP-Choline
How Does It Work?
Citicoline seems to increase a brain chemical called phosphatidylcholine. This brain chemical is important for brain function. Citicoline might also increase the amounts of other chemicals that send messages in the brain.
- Decline in memory and thinking skills that occurs normally with age. Taking citicoline seems to help memory loss in people aged 50 to 85 years.
- A group of eye disorders that can lead to vision loss (glaucoma). Taking citicoline by mouth, as a shot, or as eye drops might improve vision in some people with glaucoma.
- Stroke. Stroke patients who take citicoline by mouth or by IV within 24 hours of having the kind of stroke that is caused by a clot (ischemic stroke) are possibly more likely than other ischemic stroke patients to have a complete recovery within 3 months. Citicoline is most likely to work in people who can't receive a medicine called rtPA for their stroke.
The following doses have been studied in scientific research:
- For decline in memory and thinking skills that occurs normally with age: 1000-2000 mg of citicoline per day.
- For a group of eye disorders that can lead to vision loss (glaucoma): 500-1600 mg per day.
- For stroke: 500-2000 mg of citicoline per day starting within 24 hours of stroke.
- Healthcare providers give citicoline as a shot into the muscle for a group of eye disorders that can lead to vision loss (glaucoma). Healthcare providers also give citicoline as an injection into the vein (by IV) for decline in memory and thinking skills that occurs normally with age and to improve recovery after a stroke.
Citicoline Supplements Frequently Asked Questions
What is citicoline good for?
Citicoline is taken by mouth or given as an injection to help memory loss due to aging, improve vision in people with glaucoma, and help with recovery in stroke patients. It is also used for Alzheimer disease, Parkinson disease, bipolar disorder, lazy eye, and other conditions of the brain.
What are the side effects of citicoline?
Citicoline was well tolerated in clinical trials. Adverse effects may include GI disturbances, transient headaches, hypotension, tachycardia, bradycardia, and restlessness.
Does citicoline really work?
Neuroprotective activity of citicoline has been repeatedly shown in preclinical models of brain ischaemia and trauma, but two recent, large, pivotal clinical trials have revealed no benefits in ischaemic stroke and traumatic brain injury.
Is citicoline over the counter?
Citicoline (aka CDP-choline) is marketed as a drug in Europe and Japan and as an over-the-counter dietary supplement in the United States. ... After oral administration, citicoline has a greater than 90% bioavailability and is rapidly metabolized to cytidine and choline (5).
Can you take citicoline everyday?
Oral dosages of 250 to 2,000 mg daily have been evaluated in adolescents and adults in clinical trials. Lower doses (100 mg twice daily) have been used in short-term trials (6 weeks) with combination therapy in patients with major depressive disorder.
How long does it take citicoline to work?
Dosing of Citicoline
Both of these dosages have produced beneficial effects. Dosages as high as 2,000 mg per day have shown benefit in patients with addictive disorders, and dosages of 2,000-4,000 mg per day for 6-12 weeks produced more significant improvements than lower dosages in patients recovering from a stroke.
Does citicoline lower BP?
Conclusion. Following 4-week citicoline treatment, there were significant decrease in average nocturnal SBP and average daytime and average nighttime SBP variabilities and an increase in the number of patients with normal average daytime and average nighttime BP variabilities.
Does citicoline help ADHD?
A 2014 research review notes that citicoline supplements may help with brain and nervous system disorders like glaucoma and certain kinds of dementia. It may also help reduce symptoms of ADHD. Citicoline is a prescription medication in some countries.
What foods contain citicoline?
Foods are not a good source of citicoline, according to WebMD, but many people take a supplement of this compound --which is very similar to choline -- and well-documented for its neurological health benefits. Good sources include meat, specifically liver, beans, cruciferous vegetables and eggs.
Does citicoline work like Adderall?
Citicoline is a prescription medication in some countries. In the United States, it's sold as a supplement. Side effects of taking citicoline are not yet known, although it's nontoxic and typically well tolerated. More research is needed on its use as an alternative to Adderall for ADHD.
Is citicoline a stimulant?
The ability to increase focus and attention is generally quite good. The difference between citicoline and the stimulant per se, is the effect of citicoline is to increase the brain's concentration of dopamine, that you're encouraging the brain to make dopamine when it otherwise might not do so.
Is citicoline effective in stroke?
A single clinical trial (FI-CDPc-HIC) has used citicoline in patients with hemorrhagic stroke . ... In conclusion, citicoline is a safe and effective pharmacological product in patients with AICH and can be used in acute stroke patients even before images are obtained to separate ischemic from hemorrhagic stroke.
How does a citicoline work?
How does Citicoline work? Citicoline seems to increase a brain chemical called phosphatidylcholine. This brain chemical is important for brain function. Citicoline might also decrease brain tissue damage when the brain is injured.
Is citicoline a Nootropic?
Citicoline is considered to be a nootropic agent, meaning that it enhances focus, attention, and cognitive function in healthy individuals. Two recent placebo-controlled trials have demonstrated benefits of citicoline in healthy adults and teens.
What is citicoline 500mg?
Citicoline 500 mg - Coated tablets. Citicoline, activator of neuronal function, for symptoms related to senile involution (i.e.memory loss, cognitive aspects), as well as in post-traumatic brain injury, chronic dyskinesias, sequelae of thrombotic stroke, brain involutive and children's diseases.
What is citicoline sodium?
Citicoline is a nutritional supplement and source of choline and cytidine with potential neuroprotective and nootropic activity. Citicoline, also known as cytidine-5-diphosphocholine or CDP-choline, is hydrolyzed into cytidine and choline in the intestine.
Does citicoline cross the blood brain barrier?
The oral bioavailability of citicoline exceeds 90%, its metabolites cross the blood- brain barrier, and citicoline is resynthesized in the brain after oral consumption.
- ^ a b c d Parisi V, et al. Cytidine-5'-diphosphocholine (citicoline) improves retinal and cortical responses in patients with glaucoma. Ophthalmology. (1999)
- ^ [No authors listed. Citicoline. Monograph. Altern Med Rev. (2008)
- ^ Bracken BK, et al. Eight weeks of citicoline treatment does not perturb sleep/wake cycles in cocaine-dependent adults. Pharmacol Biochem Behav. (2011)
- ^ a b c d Sarkar AK, et al. A rapid LC-ESI-MS/MS method for the quantitation of choline, an active metabolite of citicoline: Application to in vivo pharmacokinetic and bioequivalence study in Indian healthy male volunteers. J Pharm Biomed Anal. (2012)
- ^ Gibellini F, Smith TK. The Kennedy pathway--De novo synthesis of phosphatidylethanolamine and phosphatidylcholine. IUBMB Life. (2010)
- ^ Vance JE, Vance DE. Phospholipid biosynthesis in mammalian cells. Biochem Cell Biol. (2004)
- ^ a b c d Fagone P, Jackowski S. Phosphatidylcholine and the CDP-choline cycle. Biochim Biophys Acta. (2013)
- ^ Aoyama C, Liao H, Ishidate K. Structure and function of choline kinase isoforms in mammalian cells. Prog Lipid Res. (2004)
- ^ Wu G, Vance DE. Choline kinase and its function. Biochem Cell Biol. (2010)
- ^ Jansen SM, et al. Biosynthesis of phosphatidylcholine from a phosphocholine precursor pool derived from the late endosomal/lysosomal degradation of sphingomyelin. J Biol Chem. (2001)
- ^ Jackowski S, Fagone P. CTP: Phosphocholine cytidylyltransferase: paving the way from gene to membrane. J Biol Chem. (2005)
- ^ Cornell RB, Northwood IC. Regulation of CTP:phosphocholine cytidylyltransferase by amphitropism and relocalization. Trends Biochem Sci. (2000)
- ^ Kent C. Regulatory enzymes of phosphatidylcholine biosynthesis: a personal perspective. Biochim Biophys Acta. (2005)
- ^ Cornell RB. Cholinephosphotransferase from mammalian sources. Methods Enzymol. (1992)
- ^ The enzymatic formation of lecithin from cytidine diphosphate choline and D-1,2-diglyceride.
- ^ Henneberry AL, Wistow G, McMaster CR. Cloning, genomic organization, and characterization of a human cholinephosphotransferase. J Biol Chem. (2000)
- ^ Henneberry AL, McMaster CR. Cloning and expression of a human choline/ethanolaminephosphotransferase: synthesis of phosphatidylcholine and phosphatidylethanolamine. Biochem J. (1999)
- ^ Horibata Y, Hirabayashi Y. Identification and characterization of human ethanolaminephosphotransferase1. J Lipid Res. (2007)
- ^ a b c d e Wurtman RJ, et al. Effect of oral CDP-choline on plasma choline and uridine levels in humans. Biochem Pharmacol. (2000)
- ^ a b Lopez G-Coviella I, et al. Metabolism of cytidine (5?)-diphosphocholine (cdp-choline) following oral and intravenous administration to the human and the rat. Neurochem Int. (1987)
- ^ Galletti P, et al. Biochemical rationale for the use of CDPcholine in traumatic brain injury: pharmacokinetics of the orally administered drug. J Neurol Sci. (1991)
- ^ Weiss GB. Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicoline. Life Sci. (1995)
- ^ a b c Cansev M. Uridine and cytidine in the brain: their transport and utilization. Brain Res Rev. (2006)
- ^ Vásquez JV, Pinardi G. Vasomotor responses in the isolated perfused external and internal carotid vascular beds of the rat. Gen Pharmacol. (1992)
- ^ Edvinsson L, et al. Cholinergic mechanisms in pial vessels. Histochemistry, electron microscopy and pharmacology. Z Zellforsch Mikrosk Anat. (1972)
- ^ Iwayama T, Furness JB, Burnstock G. Dual adrenergic and cholinergic innervation of the cerebral arteries of the rat. An ultrastructural study. Circ Res. (1970)
- ^ Pinardi G, et al. Effects of CDP-choline on acetylcholine-induced relaxation of the perfused carotid vascular beds of the rat. Gen Pharmacol. (1994)
- ^ López-Coviella I, et al. Evidence that 5'-cytidinediphosphocholine can affect brain phospholipid composition by increasing choline and cytidine plasma levels. J Neurochem. (1995)
- ^ a b Cansev M, et al. Cardiovascular effects of CDP-choline and its metabolites: involvement of peripheral autonomic nervous system. Eur J Pharmacol. (2007)
- ^ a b Jochem J, et al. Involvement of the histaminergic system in cytidine 5'-diphosphocholine-induced reversal of critical haemorrhagic hypotension in rats. J Physiol Pharmacol. (2010)
- ^ a b Savci V, et al. Intravenously injected CDP-choline increases blood pressure and reverses hypotension in haemorrhagic shock: effect is mediated by central cholinergic activation. Eur J Pharmacol. (2003)
- ^ a b Savci V, et al. Cardiovascular effects of intracerebroventricularly injected CDP-choline in normotensive and hypotensive animals: the involvement of cholinergic system. Naunyn Schmiedebergs Arch Pharmacol. (2002)
- ^ a b c Alvarez XA, et al. Citicoline improves memory performance in elderly subjects. Methods Find Exp Clin Pharmacol. (1997)
- ^ Silveri MM, et al. Citicoline enhances frontal lobe bioenergetics as measured by phosphorus magnetic resonance spectroscopy. NMR Biomed. (2008)
- ^ Killgore WD, et al. Citicoline affects appetite and cortico-limbic responses to images of high-calorie foods. Int J Eat Disord. (2010)
- ^ a b Improved Attentional Performance Following Citicoline Administration in Healthy Adult Women.
- ^ Rowley TJ, et al. Antinociceptive and anti-inflammatory effects of choline in a mouse model of postoperative pain. Br J Anaesth. (2010)
- ^ Yaksh TL, Dirksen R, Harty GJ. Antinociceptive effects of intrathecally injected cholinomimetic drugs in the rat and cat. Eur J Pharmacol. (1985)
- ^ Gurun MS, et al. The effect of peripherally administered CDP-choline in an acute inflammatory pain model: the role of alpha7 nicotinic acetylcholine receptor. Anesth Analg. (2009)
- ^ a b c Hamurtekin E, Gurun MS. The antinociceptive effects of centrally administered CDP-choline on acute pain models in rats: the involvement of cholinergic system. Brain Res. (2006)
- ^ a b c Bagdas D, et al. The antihyperalgesic effect of cytidine-5'-diphosphate-choline in neuropathic and inflammatory pain models. Behav Pharmacol. (2011)
- ^ Alkondon M, et al. Choline is a selective agonist of alpha7 nicotinic acetylcholine receptors in the rat brain neurons. Eur J Neurosci. (1997)
- ^ Bartolini A, et al. Role of muscarinic receptor subtypes in central antinociception. Br J Pharmacol. (1992)
- ^ Houdi AA, et al. Nicotine-induced alteration in Tyr-Gly-Gly and Met-enkephalin in discrete brain nuclei reflects altered enkephalin neuron activity. Peptides. (1991)
- ^ Zarrindast MR, Pazouki M, Nassiri-Rad S. Involvement of cholinergic and opioid receptor mechanisms in nicotine-induced antinociception. Pharmacol Toxicol. (1997)
- ^ Zarrindast MR, Nami AB, Farzin D. Nicotine potentiates morphine antinociception: a possible cholinergic mechanism. Eur Neuropsychopharmacol. (1996)
- ^ a b c d Hamurtekin E, Bagdas D, Gurun MS. Possible involvement of supraspinal opioid and GABA receptors in CDP-choline-induced antinociception in acute pain models in rats. Neurosci Lett. (2007)
- ^ Adibhatla RM, Hatcher JF, Dempsey RJ. Citicoline: neuroprotective mechanisms in cerebral ischemia. J Neurochem. (2002)
- ^ a b Plataras C, Tsakiris S, Angelogianni P. Effect of CDP-choline on brain acetylcholinesterase and Na(+), K(+)-ATPase in adult rats. Clin Biochem. (2000)
- ^ Rao AM, Hatcher JF, Dempsey RJ. Lipid alterations in transient forebrain ischemia: possible new mechanisms of CDP-choline neuroprotection. J Neurochem. (2000)
- ^ Dorman RV, Dabrowiecki Z, Horrocks LA. Effects of CDPcholine and CDPethanolamine on the alterations in rat brain lipid metabolism induced by global ischemia. J Neurochem. (1983)
- ^ Adibhatla RM, Hatcher JF, Dempsey RJ. Effects of citicoline on phospholipid and glutathione levels in transient cerebral ischemia. Stroke. (2001)
- ^ a b Krupinski J, et al. CDP-choline reduces pro-caspase and cleaved caspase-3 expression, nuclear DNA fragmentation, and specific PARP-cleaved products of caspase activation following middle cerebral artery occlusion in the rat. Neuropharmacology. (2002)
- ^ a b Gutiérrez-Fernández M, et al. CDP-choline treatment induces brain plasticity markers expression in experimental animal stroke. Neurochem Int. (2012)
- ^ Sahin S, et al. Effects of citicoline used alone and in combination with mild hypothermia on apoptosis induced by focal cerebral ischemia in rats. J Clin Neurosci. (2010)
- ^ Andersen M, et al. Effects of citicoline combined with thrombolytic therapy in a rat embolic stroke model. Stroke. (1999)
- ^ Alonso de Leciñana M, et al. Effect of combined therapy with thrombolysis and citicoline in a rat model of embolic stroke. J Neurol Sci. (2006)
- ^ Schäbitz WR, et al. The effects of prolonged treatment with citicoline in temporary experimental focal ischemia. J Neurol Sci. (1996)
- ^ Schäbitz WR, et al. Synergistic effects of a combination of low-dose basic fibroblast growth factor and citicoline after temporary experimental focal ischemia. Stroke. (1999)
- ^ a b Hurtado O, et al. Citicoline (CDP-choline) increases Sirtuin1 expression concomitant to neuroprotection in experimental stroke. J Neurochem. (2013)
- ^ a b Dixon CE, Ma X, Marion DW. Effects of CDP-choline treatment on neurobehavioral deficits after TBI and on hippocampal and neocortical acetylcholine release. J Neurotrauma. (1997)
- ^ Zafonte RD, et al. Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT). JAMA. (2012)
- ^ Dávalos A, et al. Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke. (2002)
- ^ Saver JL. Citicoline: update on a promising and widely available agent for neuroprotection and neurorepair. Rev Neurol Dis. (2008)
- ^ Dávalos A, et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet. (2012)
- ^ Amenta F, Tayebati SK. Pathways of acetylcholine synthesis, transport and release as targets for treatment of adult-onset cognitive dysfunction. Curr Med Chem. (2008)
- ^ Wang L, Albrecht MA, Wurtman RJ. Dietary supplementation with uridine-5'-monophosphate (UMP), a membrane phosphatide precursor, increases acetylcholine level and release in striatum of aged rat. Brain Res. (2007)
- ^ Tayebati SK, et al. Effect of choline-containing phospholipids on brain cholinergic transporters in the rat. J Neurol Sci. (2011)
- ^ Tomassoni D, et al. Effects of cholinergic enhancing drugs on cholinergic transporters in the brain and peripheral blood lymphocytes of spontaneously hypertensive rats. Curr Alzheimer Res. (2012)
- ^ a b c Giménez R, Raïch J, Aguilar J. Changes in brain striatum dopamine and acetylcholine receptors induced by chronic CDP-choline treatment of aging mice. Br J Pharmacol. (1991)
- ^ a b Ilcol YO, et al. Intraperitoneal administration of choline increases serum glucose in rat: involvement of the sympathoadrenal system. Horm Metab Res. (2002)
- ^ a b Ilcol YO, et al. Intraperitoneal administration of CDP-choline and its cholinergic and pyrimidinergic metabolites induce hyperglycemia in rats: involvement of the sympathoadrenal system. Arch Physiol Biochem. (2007)
- ^ Cansev M, et al. Peripheral administration of CDP-choline, phosphocholine or choline increases plasma adrenaline and noradrenaline concentrations. Auton Autacoid Pharmacol. (2008)
- ^ Saligaut C, et al. Effects of hypoxia and cytidine (5') diphosphocholine on the concentrations of dopamine, norepinephrine and metabolites in rat hypothalamus and striatum. Arch Int Pharmacodyn Ther. (1987)
- ^ a b c d Tayebati SK, et al. Modulation of monoaminergic transporters by choline-containing phospholipids in rat brain. CNS Neurol Disord Drug Targets. (2013)
- ^ Mechanism of action of CDP-choline in parkinsonism.
- ^ Wang L, et al. Dietary uridine-5'-monophosphate supplementation increases potassium-evoked dopamine release and promotes neurite outgrowth in aged rats. J Mol Neurosci. (2005)
- ^ a b c Agut J, Ortiz JA, Wurtman RJ. Cytidine (5')diphosphocholine modulates dopamine K(+)-evoked release in striatum measured by microdialysis. Ann N Y Acad Sci. (2000)
- ^ a b c d Shibuya M, et al. Effects of CDP-choline on striatal dopamine level and behavior in rats. Jpn J Pharmacol. (1981)
- ^ Dusseau JW, Hutchins PM. Stimulation of arteriolar number by salbutamol in spontaneously hypertensive rats. Am J Physiol. (1979)
- ^ Effects of apomorphine on the in vivo release of dopamine and its metabolites, studied by brain dialysis.
- ^ Radad K, et al. CDP-choline reduces dopaminergic cell loss induced by MPP(+) and glutamate in primary mesencephalic cell culture. Int J Neurosci. (2007)
- ^ Barrachina M, et al. Neuroprotective effect of citicoline in 6-hydroxydopamine-lesioned rats and in 6-hydroxydopamine-treated SH-SY5Y human neuroblastoma cells. J Neurol Sci. (2003)
- ^ Pulvirenti L, Koob GF. Dopamine receptor agonists, partial agonists and psychostimulant addiction. Trends Pharmacol Sci. (1994)
- ^ Walsh SL, et al. Fluoxetine alters the effects of intravenous cocaine in humans. J Clin Psychopharmacol. (1994)
- ^ Renshaw PF, et al. Short-term treatment with citicoline (CDP-choline) attenuates some measures of craving in cocaine-dependent subjects: a preliminary report. Psychopharmacology (Berl). (1999)
- ^ Brown ES, Gorman AR, Hynan LS. A randomized, placebo-controlled trial of citicoline add-on therapy in outpatients with bipolar disorder and cocaine dependence. J Clin Psychopharmacol. (2007)
- ^ Licata SC, et al. Effects of daily treatment with citicoline: a double-blind, placebo-controlled study in cocaine-dependent volunteers. J Addict Med. (2011)
- ^ Lukas SE, et al. Effects of short-term citicoline treatment on acute cocaine intoxication and cardiovascular effects. Psychopharmacology (Berl). (2001)
- ^ a b Teather LA, Wurtman RJ. Dietary cytidine (5')-diphosphocholine supplementation protects against development of memory deficits in aging rats. Prog Neuropsychopharmacol Biol Psychiatry. (2003)
- ^ Petkov VD, et al. Effect of CDP-choline on learning and memory processes in rodents. Methods Find Exp Clin Pharmacol. (1992)
- ^ a b Mosharrof AH, Petkov VD. Effects of citicholine and of the combination citicholine + piracetam on the memory (experiments on mice). Acta Physiol Pharmacol Bulg. (1990)
- ^ Petkov VD, Mosharrof AH, Petkov VV. Comparative studies on the effects of the nootropic drugs adafenoxate, meclofenoxate and piracetam, and of citicholine on scopolamine-impaired memory, exploratory behavior and physical capabilities (experiments on rats and mice). Acta Physiol Pharmacol Bulg. (1988)
- ^ Gallagher M, Pelleymounter MA. Spatial learning deficits in old rats: a model for memory decline in the aged. Neurobiol Aging. (1988)
- ^ Rapp PR, Rosenberg RA, Gallagher M. An evaluation of spatial information processing in aged rats. Behav Neurosci. (1987)
- ^ Albert M. Neuropsychological and neurophysiological changes in healthy adult humans across the age range. Neurobiol Aging. (1993)
- ^ Rylett RJ, et al. Acetylcholine synthesis and release following continuous intracerebral administration of NGF in adult and aged Fischer-344 rats. J Neurosci. (1993)
- ^ Ando S, et al. Turnover of synaptic membranes: age-related changes and modulation by dietary restriction. J Neurosci Res. (2002)
- ^ Salvador GA, López FM, Giusto NM. Age-related changes in central nervous system phosphatidylserine decarboxylase activity. J Neurosci Res. (2002)
- ^ Teather LA, Wurtman RJ. Chronic administration of UMP ameliorates the impairment of hippocampal-dependent memory in impoverished rats. J Nutr. (2006)
- ^ Mosharrof AH, Petkov VD, Petkov VV. Effects of meclofenoxate and citicholine on learning and memory in aged rats. Acta Physiol Pharmacol Bulg. (1987)
- ^ Spiers PA, et al. Citicoline improves verbal memory in aging. Arch Neurol. (1996)
- ^ Takasaki K, et al. Neuroprotective effects of citidine-5-diphosphocholine on impaired spatial memory in a rat model of cerebrovascular dementia. J Pharmacol Sci. (2011)
- ^ a b Ilcol YO, et al. Choline increases serum insulin in rat when injected intraperitoneally and augments basal and stimulated aceylcholine release from the rat minced pancreas in vitro. Eur J Biochem. (2003)
- ^ Cansev M, et al. Choline, CDP-choline or phosphocholine increases plasma glucagon in rats: involvement of the peripheral autonomic nervous system. Eur J Pharmacol. (2008)
- ^ Rejdak R, et al. Citicoline treatment increases retinal dopamine content in rabbits. Ophthalmic Res. (2002)
- ^ a b Parisi V, et al. Evidence of the neuroprotective role of citicoline in glaucoma patients. Prog Brain Res. (2008)
- ^ a b c d Cavun S, Savci V. CDP-choline increases plasma ACTH and potentiates the stimulated release of GH, TSH and LH: the cholinergic involvement. Fundam Clin Pharmacol. (2004)